Comparing the Effectiveness of Methylprednisolone, Dexamethasone, and Hydrocortisone in Treating Acute Respiratory Distress Syndrome

What this Trial Is About

Researchers are evaluating the effectiveness of three glucocorticoid drugsmethylprednisolone, dexamethasone, and hydrocortisonein patients with acute respiratory distress syndrome ARDS. ARDS is a serious condition caused by severe inflammation in the lungs, often following pneumonia or sepsis, leading to breathing difficulties. The study aims to compare these drugs at equivalent doses to understand their impact on inflammation and lung function in ARDS patients. The study involves three groups of 100 patients each, receiving either methylprednisolone at 1 mgkgday, dexamethasone at 13 mgday, or hydrocortisone at 350 mgday. These drugs are given during the early phase of ARDS, when inflammation is most active. The study is randomized and does not use masking. Participants receive treatment and are monitored closely during a 28-day period. Participants will be assessed for outcomes such as 28-day mortality, need for invasive mechanical ventilation, number of ventilator-free days, length of ICU stay, hospitalization duration, and occurrence of serious side effects like infections and high blood sugar. The study includes chest imaging and oxygen level monitoring to confirm ARDS diagnosis and track progress. The total participation period for each patient is 28 days from enrollment.

A Comparative Study of Glucocorticoids Efficacy in Acute Respiratory Distress Syndrome